

Dear Friend of Navigation Sciences,

I hope you are doing well and the first quarter, which went by rapidly, was productive for you. Our activity during the period focused on developing both the hardware and software components and expanding the intellectual property (IP) for the NaviSci™ System for precision lung surgery. We have also strengthened our team by appointing two highly experienced MedTech leaders as Advisors and expanded the role of one of our key engineers. Our funding efforts continue to complete the Series B financing and secure additional non-dilutive grant funding.

LSI Emerging MedTech Summit

I recently had the opportunity to present Navigation Sciences to investors and strategics at the [LSI Emerging MedTech Summit](#). This is the fifth year Navigation has participated in the conference. The meeting afforded the chance to meet with potential investors and strategics and highlight the company's achievements in translating promising academic technology from Brigham & Women's Hospital into a system progressing steadily towards a regulatory filing for market clearance. **The presentation can be viewed [here](#).**

During that time, the scope of the opportunity also has become much more apparent. Lung cancer diagnoses are increasingly at an early stage when surgery can significantly improve outcomes, and where the NaviSci System can fill an essential need by providing real-time, precision surgical navigation to assure proper tumor margins. Driving early-stage diagnoses are solid clinical data showing that X-ray CT screening improves



outcomes, reimbursement for a much larger screening population, and the emergence of minimally invasive, tissue-sparing surgery as the standard of care in early-stage tumors, based on extensive prospective studies.

Although lung cancer screening has lagged behind screening for other common tumors, such as colon, prostate, and breast cancer, stakeholders have increasingly embraced this new data. For example, the American Lung Association recently began a [campaign](#) to educate patients about lung [nodules](#) and the importance of early-stage screening.

Two New Key Advisors and Vice President Product Development

We are pleased to welcome Christopher von Jako, Ph.D., and Kurt Kruger as Advisors to the Company. They bring outstanding records of accomplishment and decades of leadership experience in finance, development, operations, and commercialization that will be central to our success as we advance.



Christopher von Jako, Ph.D.



Kurt Kruger

Underscoring the growing scope of development activities as we move towards our FDA submission, Larry Roth, who for more than two years has been the engineering lead on the development of the NaviSci EndoMarker™, our bronchoscopy-based tissue marker for tumor localization, has agreed to take on an expanded role as Vice President Product Development. Larry will oversee all aspects of design engineering, the quality system, and FDA documentation requirements.

Expanding Patent Coverage

We recently received notice of allowances for two patents, one for Europe and one for the U.S. The European application, which covers the primary technology for the NaviSci System licensed from Brigham & Women's Hospital, will be the first to be issued in Europe. The U.S. Patent is a continuation-in-part to U.S. Patent No. 11,058,494, strengthening our primary patent claims. The U.S. patent will be the fourth issued patent covering Navigation's technology.

As always, thank you for your support.

Sincerely,

Alan Lucas, CEO, Navigation Sciences, Inc.
Alan.lucas@navigationsci.com +1-617-834-2829



Navigation Sciences
Executive Summary



Entering the Era of
"Precision Cancer Surgery"



Navigation Sciences
Corporate PPT